The abstracts will be available on the AACR 2025 meeting website. The posters will be available online at Erasca.com/science/presentations following the presentations.

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class i targeted and immune-mediated therapeutics to fight cancer, today announced that an ...

The abstracts will be available on the AACR 2025 meeting website. The posters will be available ... regarding our development plans and trial designs; our ability to fund our operating plans ...

Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety ...

All statements that are not historical facts are forward-looking statements, including any statements regarding: the design, initiation, progress, timing, scope and results of clinical trials ...

All statements that are not historical facts are forward-looking statements, including any statements regarding: the design, initiation, progress, timing, scope and results of clinical trials, ...

Update on IND-enabling data for MP0712, a Radio-DARPin targeting DLL3 and labeled with 212Pb, co-developed with Orano Med; entering FIH studies in 2025 for the treatment of small cell lung cancer Firs ...

The specialist painting, although subtle, is high impact. It’s the one thing that reduces my guests’ pulse rates as they ...